Ignite Creation Date:
2024-05-06 @ 4:17 PM
Last Modification Date:
2024-10-26 @ 2:07 PM
Study NCT ID:
NCT04933227
Status:
TERMINATED
Last Update Posted:
2024-03-12
First Post:
2021-06-17
Brief Title:
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction GEJ
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Organization Data
Organization:
Hoffmann-La Roche
Class:
INDUSTRY
Study ID:
ML42913
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hoffmann-La Roche
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None